NPPA fixes the prices of various drugs under the Drugs (Prices Control) Order, 2013 as on 2018-02-08

Feb 08, 2018 | by Avantis RegTech Legal Research Team

A |  A

National Pharmaceutical Pricing Authority (NPPA) vide order dated February 06, 2018 has fixed the ceiling prices of various drugs under the Drugs (Prices Control) Order, 2013 such as:

·       Paracetamol + Dicyclomine Tablet (Pacimol Spas)

·       Amoxicilin Potasium Clavulanate Tablet (Clavam Forte DT)

·       Telmisartan + Chlorthalidone Tablet (Tigatel CH40

·       Cilnidipine + Telmisartan tablet (Telvacil 80mg)

·       Metoprolol ER Tablet

·       Levetiracetam Table

·       Phenylephrine + Chlorpheniramine Syrup

·       Human Insulin Injection

·       Docretaxel Injection (Docretaxel IP 120mg/3ml)

·       Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozucor Gold 10)

·       Amoxycillin + Clavulante Suspension

·       Etoricoxib + Paracetamol Tablet (Etomax P)

All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price

All the existing manufacturers having MRP lower than the ceiling price shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013

The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price

The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers

The manufacturers shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

[S. O. 544(E)]




Related Updates

Alternate Text

Get updates on the go on RuleZbook Mobile App.